Stock Code: 603707 Stock Abbreviation: King-friend Pharma Announcement No.: 2026-040

Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.

Announcement on the Subsidiary's Receipt of the U.S. FDA Registration Approval for the Transfer of the Manufacturing Site of Desmopressin Acetate Injection

The Board of Directors and all directors of the Company warrant that there are no false records, misleading statements or material omissions in the contents of this announcement, and they shall bear individual and joint and several legal liability for the truthfulness, accuracy and completeness of its contents.

The subsidiary of Nanjing King-friend Biochemical Pharmaceutical Co., Ltd. (hereinafter referred to as "King-friend Pharma" or the "Company"), Meitheal Pharmaceuticals, Inc. (hereinafter referred to as "Meitheal"), has recently received an approval letter issued by the U.S. Food and Drug Administration (hereinafter referred to as the "U.S. FDA") for the transfer of the manufacturing site of Desmopressin Acetate Injection, 4 mcg/mL and 40 mcg/10 mL (ANDA No.: 074888), approving manufacture at the facility of Kindos Pharmaceutical Co., Ltd., a subsidiary of the Company. The relevant details are hereby announced as follows:

I. Basic Information about the Drug

(I) Drug Name	Desmopressin Acetate Injection
(II) Indications	Central diabetes insipidus; hemostatic management during surgery or trauma in patients with hemophilia A and type 1 von Willebrand disease.
(III) Dosage Form	Injection
(IV) Strengths	4 mcg/mL and 40 mcg/10 mL
(V) ANDA No.	074888
(VI) Applicant	Meitheal Pharmaceuticals, Inc.

II. Other Relevant Information about the Drug

The Company has recently received a notice from the U.S. FDA that the application filed by the Company's subsidiary Meitheal with the U.S. FDA for the transfer of the manufacturing site of Desmopressin Acetate Injection, 4 mcg/mL and 40 mcg/10 mL (ANDA No.: 074888), to Kindos Pharmaceutical Co., Ltd., has been approved.

The reference listed drug for Desmopressin Acetate Injection is held by J MOLNER HOLDINGS INC and was approved for marketing by the U.S. FDA on March 30, 1984 under the trade name DDAVP. Desmopressin Acetate Injection, 4 mcg/mL and 40 mcg/10 mL (ANDA No.: 074888), was approved for marketing by the U.S. FDA on October 15, 1997 and was originally held by Teva Pharmaceuticals USA, Inc.; it is now purchased and held by the Company's subsidiary Meitheal Pharmaceuticals, Inc.

According to publicly available information, there are currently 5 other generic versions of Desmopressin Acetate Injection being marketed in the United States (CAPLIN STERILES LTD, DR REDDYS LABORATORIES LTD, GLAND PHARMA LTD, SAGENT PHARMACEUTICALS INC, UBI PHARMA INC).

As of the date of this announcement, the Company has invested approximately RMB 477.52 ten-thousand yuan (approximately RMB 4.78 million) in research and development expenses on the Desmopressin Acetate Injection manufacturing site transfer project.

III. Impact on the Company

This approval confirms that the Company's aseptic injectable production line and quality system meet the U.S. cGMP standards, enriches the Company's injectable product pipeline for medical institutions in North America, and improves its overseas proprietary supply chain system. It is expected to have a positive impact on the Company's operating results in the medium to long term.

IV. Risk Warning

The Company attaches great importance to pharmaceutical research and development and strictly controls the quality and safety of pharmaceutical research and development, production and sales. However, the production and sales of products are susceptible to uncertain factors such as national policies and market conditions, and there may be circumstances such as sales falling short of expectations. Investors are kindly advised to make prudent decisions and be mindful of guarding against investment risks.

It is hereby announced.

Board of Directors of Nanjing King-friend Biochemical Pharmaceutical Co., Ltd.

July 4, 2026